2021 World Conference on Lung Cancer (Posters)-FP04. Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

FP04. Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Back to course

Video Transcription

Video Summary

Professor Igor Bondarenko from the Dnipropetrovsk Medical Academy in Ukraine shared the results of a subgroup analysis focusing on patients with locally advanced non-small cell lung cancer. The analysis, which was part of the Phase 3 Empower Lung 1 study, found that first-line semi-plumab monotherapy showed superior survival benefits compared to chemotherapy in patients with advanced non-small cell lung cancer without driver mutations and with PD-L1 expression of 50% or more. The safety profile of semi-plumab was comparable to other PD-1 inhibitors. The analysis supports the use of first-line semi-plumab monotherapy in this patient population.

Asset Subtitle

Igor Bondarenko

Meta Tag

Speaker Igor Bondarenko

Topic Immunotherapy (Phase II/III Trials)

Keywords

subgroup analysis

semi-plumab monotherapy

survival benefits

PD-L1 expression

patient population